BioLineRx Ltd.
BLRX
$2.72
-$0.22-7.48%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 62.03% | 30.42% | -52.71% | -142.93% | -123.01% |
| Total Depreciation and Amortization | 230.64% | 181.18% | 165.27% | 102.60% | 34.95% |
| Total Amortization of Deferred Charges | -- | -65.50% | -65.50% | -65.50% | -100.00% |
| Total Other Non-Cash Items | -139.68% | -104.02% | 1,029.77% | 739.11% | 522.40% |
| Change in Net Operating Assets | -481.66% | -394.12% | 210.38% | 1,127.71% | 206.99% |
| Cash from Operations | 9.04% | 5.35% | -0.11% | 13.84% | -27.71% |
| Capital Expenditure | 52.23% | 54.76% | 20.00% | 11.45% | 8.19% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -108.13% | -219.64% | 102.00% | -62.29% | 499.54% |
| Cash from Investing | -108.47% | -223.80% | 105.16% | -63.95% | 520.50% |
| Total Debt Issued | 3,557.37% | 110.64% | -- | -- | -105.74% |
| Total Debt Repaid | -203.86% | -170.26% | -31.28% | 34.86% | 68.61% |
| Issuance of Common Stock | 308.82% | 60.39% | 18.66% | 18.66% | -71.25% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,155.41% | 74.64% | -33.38% | -26.33% | -87.45% |
| Foreign Exchange rate Adjustments | 111.16% | 74.04% | 88.32% | 63.10% | -48.88% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 120.62% | 87.65% | -29.24% | -163.50% | -453.29% |
